Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,136 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,136 Papers indexed
1,440 Papers AI scored
40,136 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-06 10:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40136 results
B
AI -
Standard 71.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.5/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 10.0; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
Immune cell profiling of peripheral blood in long-term testicular germ cell tumor survivors.
PMID 41322405 Published: 2025-11-13 Ingested: 2026-08-02 12:03 AM Frontiers in immunology
AI -
Standard 71.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 60.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 71.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 60.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Minimally invasive versus open surgery for pediatric Wilms tumor: A systematic review and meta-analysis under SIOP guidelines.
PMID 41219039 Published: 2025-10-30 Ingested: 2026-08-02 12:05 AM Journal of pediatric urology
AI -
Standard 71.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.5/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 10.0; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
Cervical spine arthritis as initial manifestation in Juvenile Idiopathic Arthritis: a multicenter retrospective study.
PMID 41214682 Published: 2025-11-10 Ingested: 2026-08-02 12:05 AM Pediatric rheumatology online journal
AI -
Standard 71.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.5/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 60.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
Screening for gonadal malignancy in androgen insensitivity syndrome: A systematic review.
PMID 41102125 Published: 2025-09-30 Ingested: 2026-08-02 12:05 AM Journal of pediatric urology
AI -
Standard 71.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.5/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 10.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 71.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.5/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 10.0; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 65.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 71.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 70.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 579 of 3345
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic